At P.I. Celkem, we are deeply committed to supporting research on Idiopathic Pulmonary Fibrosis (IPF), a serious and life-threatening condition with limited treatment options. IPF research represents a significant challenge, as most patients face a life expectancy of only a few years after diagnosis. While we focus on producing high-quality biomolecular proteins for various research applications, our ultimate goal is to help fund critical IPF research, helping advance treatments for this devastating disease.Read our blogs below to learn more about IPF.
Pulmonary Fibrosis Warriors
Check out this great video about PF Warriors. 
Experimental anticancer drug shows promise!
It all begins with an idea.
Two FDA-approved drugs, nintedanib and pirfenidone, are currently used to slow IPF disease progression, but they have side effects and do not completely relieve symptoms or cure the disease. Better drugs are needed, the researchers said.
In the new study, the researchers identified saracatinib as a candidate for treating IPF by using computational predictions that screened drug candidates for anti-fibrotic effects. The researchers then exposed the drug to human lung cells in culture and found that it could reverse the disease signature of IPF.